New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:02 EDTLLYEli Lilly announces EC approval of Jardiance tablets for use in adults
The European Commission granted marketing authorization for Jardiance tablets, a sodium glucose co-transporter 2 inhibitor, for the treatment of type 2 diabetes mellitus to improve glycemic control in adults in Europe, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly announced. The European Commission approved Jardiance 10 and 25 mg once daily tablets for use when diet and exercise alone do not provide adequate glycemic control. Jardiance may be used alone when metformin is not considered appropriate due to intolerance, or alongside other glucose-lowering medicines including insulin, when glucose control is inadequate.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
09:29 EDTLLYEli Lilly sees ForEx to have a negative impact of 4c in 2015 EPS
Subscribe for More Information
07:20 EDTLLYEli Lilly CEO Lechleiter says currency fluctuations hitting topline
Subscribe for More Information
06:38 EDTLLYEli Lilly reports Q4 Cialis sales $622.4M vs. $588.3M last year
Subscribe for More Information
06:30 EDTLLYEli Lilly FY15 EPS guidance does not include 12c potential charge
Subscribe for More Information
06:28 EDTLLYEli Lilly backs FY15 EPS view of $3.10-$3.20, consensus $3.18
Lowers FY15 revenue guidance to $19.5B-$20B from $20.3B-$20.8B, consensus $20.67B.
06:26 EDTLLYEli Lilly reports Q4 EPS 75c, consensus 74c
Subscribe for More Information
January 29, 2015
15:37 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
13:36 EDTLLYEli Lilly volatility elevated into Q4 and outlook
Subscribe for More Information
13:29 EDTLLYEarnings Preview: Eli Lilly to report Q4 results amid new product launches
Subscribe for More Information
12:00 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.
January 21, 2015
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use